Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | CA7 | P43166 | 2/20 | 0.51 |
| ▸ | CTSK | P43235 | 9/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1414128 | 0.87 | CA1 (0.63) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL24691446 | 0.87 | CA1 (0.63) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL1414299 | 0.87 | CA1 (0.63) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL2987820 | 0.86 | CA1 (0.53) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL385451 | 0.86 | CA1 (0.53) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL168390 | 0.84 | CA1 (0.54) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL2104826 | 0.83 | CA1 (0.50) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL25269853 | 0.83 | CA1 (0.49) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL25269854 | 0.83 | CA1 (0.49) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL7119554 | 0.80 | CA1 (0.49) | CA1CA2CA7CTSKCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163919-B2 | Imidazopyridinyl benzamide mitotic kinesin inhibitors | CYTOKINETICS, INCORPORATED (US) | 2012-04-24 | — | — | US | disclosed |
| US-20100069453-A1 | Certain Chemical Entities, Compositions, and Methods | CYTOKINETICS, INC. | 2010-03-18 | — | — | US | disclosed |
| US-20060247289-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069453-A1 | Certain Chemical Entities, Compositions, and Methods | KIF5B, KIF2C, PLK1 | CA1 3116/4885CA2 2238/4885CA7 3394/4885 |
| US-20060247289-A1 | Certain chemical entities, compositions, and methods | KIF5B, KIF2C, PLK1 | CA1 3116/4885CA2 2238/4885CA7 3394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.